These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35106500)

  • 1. Protocol for integrative subtyping of lower-grade gliomas using the SUMO pipeline.
    Sienkiewicz K; Ratan A
    STAR Protoc; 2022 Mar; 3(1):101110. PubMed ID: 35106500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating multi-platform genomic datasets for kidney renal clear cell carcinoma subtyping using stacked denoising autoencoders.
    Gu T; Zhao X
    Sci Rep; 2019 Nov; 9(1):16668. PubMed ID: 31723226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting molecular subtypes from multi-omics datasets using SUMO.
    Sienkiewicz K; Chen J; Chatrath A; Lawson JT; Sheffield NC; Zhang L; Ratan A
    Cell Rep Methods; 2022 Jan; 2(1):. PubMed ID: 35211690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer.
    Robertson AG; Yau C; Carrot-Zhang J; Damrauer JS; Knijnenburg TA; Chambwe N; Hoadley KA; Kemal A; Zenklusen JC; Cherniack AD; Beroukhim R; Zhou W
    STAR Protoc; 2021 Jun; 2(2):100483. PubMed ID: 33982016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-project and Multi-profile joint Non-negative Matrix Factorization for cancer omic datasets.
    Salazar DA; Pržulj N; Valencia CF
    Bioinformatics; 2021 Dec; 37(24):4801-4809. PubMed ID: 34375392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computational pipeline to visualize DNA-protein binding states using dSMF data.
    Rao S; Ramachandran S
    STAR Protoc; 2022 Jun; 3(2):101299. PubMed ID: 35463472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated bioinformatic pipeline using whole-exome and RNAseq data to identify germline variants correlated with cancer.
    Sahu D; Chatrath A; Ratan A; Dutta A
    STAR Protoc; 2022 Jun; 3(2):101273. PubMed ID: 35403010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MICRORNA-AUGMENTED PATHWAYS (mirAP) AND THEIR APPLICATIONS TO PATHWAY ANALYSIS AND DISEASE SUBTYPING.
    Diaz D; Donato M; Nguyen T; Draghici S
    Pac Symp Biocomput; 2017; 22():390-401. PubMed ID: 27896992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical Methods for Integrative Clustering of Multi-omics Data.
    Chalise P; Kwon D; Fridley BL; Mo Q
    Methods Mol Biol; 2023; 2629():73-93. PubMed ID: 36929074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG).
    Liu H; Wang J; Luo T; Zhen Z; Liu L; Zheng Y; Zhang C; Hu X
    Front Endocrinol (Lausanne); 2022; 13():1106120. PubMed ID: 36714574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.
    Zeng WJ; Yang YL; Liu ZZ; Wen ZP; Chen YH; Hu XL; Cheng Q; Xiao J; Zhao J; Chen XP
    Cell Physiol Biochem; 2018; 47(1):428-439. PubMed ID: 29794476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for dissecting cascade computational components in neural networks of a visual system.
    Jia S; Liu JK; Yu Z
    STAR Protoc; 2023 Dec; 4(4):102722. PubMed ID: 37976152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DeepAutoGlioma: a deep learning autoencoder-based multi-omics data integration and classification tools for glioma subtyping.
    Munquad S; Das AB
    BioData Min; 2023 Nov; 16(1):32. PubMed ID: 37968655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GliomaDB: A Web Server for Integrating Glioma Omics Data and Interactive Analysis.
    Yang Y; Sui Y; Xie B; Qu H; Fang X
    Genomics Proteomics Bioinformatics; 2019 Aug; 17(4):465-471. PubMed ID: 31811943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCNF: A Novel Method for Cancer Subtyping by Integrating Multi-Omics and Clinical Data.
    Zhao L; Yan H
    IEEE/ACM Trans Comput Biol Bioinform; 2020; 17(5):1682-1690. PubMed ID: 30990192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.